FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4223521433> ?p ?o ?g. }

• W4223521433 endingPage "2980" @default.
• W4223521433 startingPage "2972" @default.
• W4223521433 abstract "The purpose of this phase I clinical trial is to assess the safety and tolerability of allogeneic adipose tissue-derived stem cells (ADSCs) among chronic kidney disease (CKD) patients. 12 eligible CKD patients with an estimated glomerular filtration rate (eGFR) of 15-44 ml/min/1.73 m2 received one dose of intravenous allogeneic ADSCs (ELIXCYTE® ), as 3 groups: 3 low dose (6.4 × 107 cells in total of 8 ml), 3 middle dose (19.2 × 107 cells in total of 24 ml) and 6 high dose (32.0 × 107 cells in total of 40 ml) of ELIXCYTE® and evaluated after 48 weeks. Primary endpoint was the safety profiles in terms of incidence of adverse events (AEs) and serious adverse event (SAE). Two subjects in high dose group experienced a total of 2 treatment-related AEs which are Grade 1 slow speech and Grade 1 bradyphrenia after the infusion. One subject in middle dose group experienced an SAE unlikely related to treatment, grade 2 proteinuria. No fatal AE was reported in this study. An increase in eGFR was observed in 7 out of 12 subjects (58%) at Week 24 and in 6 of 12 subjects (50%) by Week 48. By Week 24, an increase in eGFR by more than 20% among all CKD patients with baseline eGFR ≧ 30 ml/min/1.73 m2 as compared to only 2 subjects in baseline eGFR < 30 ml/min/1.73 m2 group. No significant reduction in proteinuria was noted among all subjects. This phase I trial demonstrated single-dose intravenous ELIXCYTE was well tolerated in moderate-to-severe CKD patients and its preliminary efficacy warrants future studies." @default.
• W4223521433 created "2022-04-15" @default.
• W4223521433 creator A5001896744 @default.
• W4223521433 creator A5015260770 @default.
• W4223521433 creator A5024610125 @default.
• W4223521433 creator A5034969040 @default.
• W4223521433 creator A5035104975 @default.
• W4223521433 creator A5053873074 @default.
• W4223521433 creator A5061973328 @default.
• W4223521433 creator A5072219208 @default.
• W4223521433 creator A5076790329 @default.
• W4223521433 creator A5077022477 @default.
• W4223521433 creator A5082319391 @default.
• W4223521433 creator A5082791789 @default.
• W4223521433 date "2022-04-12" @default.
• W4223521433 modified "2023-10-04" @default.
• W4223521433 title "Allogeneic adipose tissue‐derived stem cells ELIXCYTE ^® in chronic kidney disease: A phase I study assessing safety and clinical feasibility" @default.
• W4223521433 cites W1965675690 @default.
• W4223521433 cites W1976371737 @default.
• W4223521433 cites W1992666640 @default.
• W4223521433 cites W2004650050 @default.
• W4223521433 cites W2005477804 @default.
• W4223521433 cites W2021634519 @default.
• W4223521433 cites W2043922598 @default.
• W4223521433 cites W2061415261 @default.
• W4223521433 cites W2068003621 @default.
• W4223521433 cites W2075300862 @default.
• W4223521433 cites W2091107766 @default.
• W4223521433 cites W2091203020 @default.
• W4223521433 cites W2098577659 @default.
• W4223521433 cites W2109190880 @default.
• W4223521433 cites W2115062578 @default.
• W4223521433 cites W2116086770 @default.
• W4223521433 cites W2118100479 @default.
• W4223521433 cites W2119055978 @default.
• W4223521433 cites W2126118046 @default.
• W4223521433 cites W2140364077 @default.
• W4223521433 cites W2141832516 @default.
• W4223521433 cites W2144405682 @default.
• W4223521433 cites W2158458517 @default.
• W4223521433 cites W2169367453 @default.
• W4223521433 cites W2470481127 @default.
• W4223521433 cites W2520436302 @default.
• W4223521433 cites W2582602949 @default.
• W4223521433 cites W2615171917 @default.
• W4223521433 cites W4211025575 @default.
• W4223521433 cites W4223521433 @default.
• W4223521433 doi "https://doi.org/10.1111/jcmm.17310" @default.
• W4223521433 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35415928" @default.
• W4223521433 hasPublicationYear "2022" @default.
• W4223521433 type Work @default.
• W4223521433 citedByCount "2" @default.
• W4223521433 countsByYear W42235214332022 @default.
• W4223521433 countsByYear W42235214332023 @default.
• W4223521433 crossrefType "journal-article" @default.
• W4223521433 hasAuthorship W4223521433A5001896744 @default.
• W4223521433 hasAuthorship W4223521433A5015260770 @default.
• W4223521433 hasAuthorship W4223521433A5024610125 @default.
• W4223521433 hasAuthorship W4223521433A5034969040 @default.
• W4223521433 hasAuthorship W4223521433A5035104975 @default.
• W4223521433 hasAuthorship W4223521433A5053873074 @default.
• W4223521433 hasAuthorship W4223521433A5061973328 @default.
• W4223521433 hasAuthorship W4223521433A5072219208 @default.
• W4223521433 hasAuthorship W4223521433A5076790329 @default.
• W4223521433 hasAuthorship W4223521433A5077022477 @default.
• W4223521433 hasAuthorship W4223521433A5082319391 @default.
• W4223521433 hasAuthorship W4223521433A5082791789 @default.
• W4223521433 hasBestOaLocation W42235214331 @default.
• W4223521433 hasConcept C120665830 @default.
• W4223521433 hasConcept C121332964 @default.
• W4223521433 hasConcept C126322002 @default.
• W4223521433 hasConcept C126894567 @default.
• W4223521433 hasConcept C159641895 @default.
• W4223521433 hasConcept C171089720 @default.
• W4223521433 hasConcept C197934379 @default.
• W4223521433 hasConcept C203092338 @default.
• W4223521433 hasConcept C2778375690 @default.
• W4223521433 hasConcept C2778653478 @default.
• W4223521433 hasConcept C2779561371 @default.
• W4223521433 hasConcept C2780091579 @default.
• W4223521433 hasConcept C535046627 @default.
• W4223521433 hasConcept C61511704 @default.
• W4223521433 hasConcept C71924100 @default.
• W4223521433 hasConceptScore W4223521433C120665830 @default.
• W4223521433 hasConceptScore W4223521433C121332964 @default.
• W4223521433 hasConceptScore W4223521433C126322002 @default.
• W4223521433 hasConceptScore W4223521433C126894567 @default.
• W4223521433 hasConceptScore W4223521433C159641895 @default.
• W4223521433 hasConceptScore W4223521433C171089720 @default.
• W4223521433 hasConceptScore W4223521433C197934379 @default.
• W4223521433 hasConceptScore W4223521433C203092338 @default.
• W4223521433 hasConceptScore W4223521433C2778375690 @default.
• W4223521433 hasConceptScore W4223521433C2778653478 @default.
• W4223521433 hasConceptScore W4223521433C2779561371 @default.
• W4223521433 hasConceptScore W4223521433C2780091579 @default.
• W4223521433 hasConceptScore W4223521433C535046627 @default.
• W4223521433 hasConceptScore W4223521433C61511704 @default.
• W4223521433 hasConceptScore W4223521433C71924100 @default.

• next